Status:
COMPLETED
Efficacy and Safety of Eletriptan for the Treatment of Migraine in Patients Not Satisfied With Rizatriptan Therapy
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Migraine
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
To assess the efficacy and safety of eletriptan for migraine headaches in subjects who were not satisfied with rizatriptan therapy
Eligibility Criteria
Inclusion
- Diagnosis of migraine headache according to International Headache Society criteria and migraine headaches for at least 1 year
- Eletriptan naive
- Previously treated with rizatriptan and failed to achieve a satisfactory response within the past 12 months
Exclusion
- Non-migraine headaches on average more than 6 days per month or have less than 24 hours of freedom from headache between migraine attacks
- Migraine attacks that are atypical or chronic daily headaches
- A history of migraine with prolonged aura, familial hemiplegic migraine, basilar migraine, migrainous infarction, migraine aura without headache, migraine with acute onset aura
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2003
Estimated Enrollment :
127 Patients enrolled
Trial Details
Trial ID
NCT00632385
Start Date
January 1 2003
End Date
August 1 2003
Last Update
January 27 2021
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Irvine, California, United States, 92618
2
Pfizer Investigational Site
Newport Beach, California, United States, 92660-2452
3
Pfizer Investigational Site
San Francisco, California, United States, 94109
4
Pfizer Investigational Site
Plantation, Florida, United States, 33324